UBS Group’s Windtree Therapeutics Inc WINT Stock Holding History

UBS Group’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-8,444	Closed	-$10K	–	8368
2017 Q1	$10K	Sell	8,444 -2,340	-22%	-$3.04K	﹤0.01%	6648
2016 Q4	$14K	Sell	10,784 -5,409	-33%	-$9.99K	﹤0.01%	6748
2016 Q3	$41K	Buy	16,193 +293	+2%	+$638	﹤0.01%	5687
2016 Q2	$31K	Buy	15,900 +11,234	+241%	+$27.2K	﹤0.01%	5920
2016 Q1	$8K	Sell	4,666 -3,078	-40%	-$6.61K	﹤0.01%	6818
2015 Q4	$24K	Buy	7,744 +5,727	+284%	+$23.5K	﹤0.01%	6580
2015 Q3	$9K	Buy	2,017 +1,027	+104%	+$6.8K	﹤0.01%	7375
2015 Q2	$9K	Sell	990 -296	-23%	-$4.16K	﹤0.01%	7578
2015 Q1	$22K	Buy	1,286 +280	+28%	+$5.51K	﹤0.01%	6919
2014 Q4	$16K	Buy	+1,006	New	+$22.1K	﹤0.01%	7986

Other funds holding WINT

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

UBS Group's WINT Position: Q2 2017 in Review

UBS Group sold out of Windtree Therapeutics Inc (WINT) in Q2 2017, closing a stake of 8,444 shares — an estimated $10K sold.

UBS Group first reported a position in WINT in Q4 2014 and held it in 10 quarters. The position peaked at $41K in Q3 2016. 3 funds tracked by Wall St. Rank hold WINT as of Q2 2017.

UBS Group reported no remaining Windtree Therapeutics Inc position as of Q2 2017 after selling out during the quarter.
UBS Group sold 8,444 Windtree Therapeutics Inc shares in Q2 2017, an estimated $10K.
UBS Group first reported a position in Windtree Therapeutics Inc in Q4 2014 and held it in 10 quarters.
UBS Group's Windtree Therapeutics Inc position peaked at $41K in Q3 2016.
3 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q2 2017.

Based on UBS Group's 13F filing for Q2 2017, filed 14 Aug 2017.